Assistant Professor
Oncology
Dr. Sumanta K. Pal, MD
|
|
Give Review
Sumanta practices Oncology. He graduated from David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13 in research and 7 in primary care medicine Sumanta K. Pal has written publications. He has 100 publications published with PubMed. The lastest publication is: 'Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.' He is registered with Medicare.
Publications
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary Bladder reveals a high frequency of clinically relevant genomic...
- Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine.
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
- Cabazitaxel for the therapy of metastatic castration-resistant prostate Cancer in the aftermath of the CHAARTED trial.
- Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche in high-risk localized prostate Cancer.
- Overview and management of toxicities associated with Systemic therapies for advanced renal cell carcinoma.
- Conditional Survival in de novo Metastatic Urothelial Carcinoma.
- Development of PROSTVAC immunotherapy in prostate Cancer.
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladde...
- TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
- PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.
- Stool bacteriomic profiling in patients with metastatic renal cell Carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors.
- Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
- Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
- Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases.
- Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
- A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
- TLR9 signaling through NF-kappaB/RELA and STAT3 promotes tumor-propagating potential of prostate Cancer cells.
- PIWI-interacting RNAs are dysregulated in renal cell carcinoma and associated with tumor metastasis and Cancer specific survival.
- A phase I trial of mushroom powder in patients with biochemically recurrent prostate Cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bispo...
- Circulating tumor cells in prostate Cancer: Does (nuclear) size matter?
- SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sen...
- Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell Carcinoma...
- Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal Analysis of cytokine profile.
- Activin receptor inhibitors-dalantercept.
- Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell Carcinoma: evidence from a nationwide sample of...
- Cisplatin-based first-line therapy for advanced urothelial Carcinoma after previous perioperative cisplatin-based therapy.
- Detection and phenotyping of circulating tumor cells in high-risk localized prostate Cancer.
- Outcome of patients with metastatic sarcomatoid renal cell Carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell Carcinoma previously treated w...
- RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell Carcinoma.
- Ipilimumab in the treatment of prostate Cancer.
- Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
- Sequencing systemic therapies for metastatic kidney Cancer.
- Geography: an increasingly important variable in prostate Cancer clinical trials.
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell Carcinoma.
- Lifetime cost of everolimus vs axitinib in patients with advanced renal cell Carcinoma who failed prior sunitinib therapy in the US.
- The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy Cancer radiotherapy.
- CD8(+) T-Cell immunosurveillance constrains lymphoid pre-metastatic myeloid Cell accumulation.
- Prostate Cancer: The best fit for enzalutamide in metastatic prostate Cancer.
- Metastatic adrenocortical Carcinoma with a prolonged response to mitotane.
- Comparative effectiveness of second-line targeted therapies for metastatic renal cell Carcinoma: synthesis of findings from two multi-practice chart reviews in the Uni...
- Treatment patterns in metastatic renal cell Carcinoma: a retrospective review of medical records from US community oncology practices.
- CytoreDuctive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Co...
- Programmed death-1 inhibition in renal cell Carcinoma: clinical insights and future directions.
- Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future.
- Management of localized prostate Cancer: the pendulum swings (back to the middle).
- Preoperative androgen deprivation therapy for localized prostate Cancer: delayed biochemical recurrence in high-risk disease.
- First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell C...
- Survival outcome and treatment response of patients with late relapse from renal cell Carcinoma in the era of targeted therapy.
- Radium-223 in metastatic castration resistant prostate Cancer.
- The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer...
- Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling.
- Ramucirumab in metastatic renal cell Carcinoma: The beginning or the end?
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy.
- Novel tyrosine kinase inhibitors for renal cell Carcinoma.
- TLR9 signaling in the tumor microenvironment initiates Cancer recurrence after radiotherapy.
- Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell Carcinoma.
- Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective Analysis☆
- Role of biopsychosocial screening in Cancer care.
- A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database Analysis.
- Metastatic non-clear cell renal cell Carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Dat...
- A new age for vaccine therapy in renal cell Carcinoma.
- Optimizing systemic therapy for bladder Cancer.
- B Cells promote tumor progression via STAT3 regulated-angiogenesis.
- Penile Cancer: Clinical Practice Guidelines in Oncology.
- Quality of life in patients with metastatic renal cell Carcinoma: assessment of long-term survivors.
- Paclitaxel-based high-dose chemotherapy with autologous stem Cell rescue for relapsed germ Cell tumor: clinical outcome and quality of life in long-term survivors.
- Pooled analysis of clinical outcomes with neoadjuvant Cisplatin and gemcitabine chemotherapy for muscle invasive bladder Cancer.
- Sequential treatment strategies and combination therapy regimens in metastatic renal cell Carcinoma.
- Targeting angiopoietin-2 signaling in Cancer therapy.
- Enzalutamide for the treatment of prostate Cancer.
- A "game of thrones" in metastatic renal cell Carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors batt...
- Differentiating mTOR inhibitors in renal cell Carcinoma.
- Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer.
- TLR9-mediated siRNA deLivery for targeting of normal and malignant human hematopoietic cells in vivo.
- Preoperative therapy for localized prostate Cancer: a comprehensive overview.
- Abiraterone and its place in the treatment of metastatic CRPC.
- Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast Cancer.
- Tivozanib : current status and future directions in the treatment of solid Tumors.
- Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate Cancer.
- Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder Cancer.
- Management of docetaxel failures in metastatic castrate-resistant prostate Cancer.
- Lessons learned from the bevacizumab experience.
- Chemotherapy-induced nausea and vomiting in Asian women with breast Cancer receiving anthracycline-based adjuvant chemotherapy.
- Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell Carcinoma.
- S1PR1-STAT3 signaling is crucial for myeloid Cell colonization at future metastatic sites.
- Identification of a 4-microRNA signature for clear cell renal cell Carcinoma metastasis and prognosis.
- Novel therapies for metastatic renal cell Carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.
- Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
- Nursing considerations with pazopanib therapy: focus on metastatic renal cell Carcinoma.
- Managing refractory metastatic renal cell Carcinoma: a RECORD spinning on a tilted AXIS.
- Role of surgery for locally advanced and metastatic renal cell Carcinoma.
- Recent advances in the therapy of castration-resistant prostate Cancer: the price of progress.
- Current paradigms and evolving concepts in metastatic castration-resistant prostate Cancer.
- New therapies for castrate-resistant prostate Cancer.
- Systemic therapies for metastatic renal cell carcinoma in older adults.
- Unraveling the role of hypoxia-inducible factor in renal cell Carcinoma: a biological and therapeutic perspective.
- Overcoming chemotherapy resistance in prostate Cancer.
Schools
David Geffen School Of Medicine At UCLA
UCLA Medical Center
Harbor UCLA Medical Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- Affiliated Health Funds PPO
- Beech Street (Multiplan) PPO
- Benefit Panel Services PPO
- Blue Shield of California HMO
- Blue Shield of California PPO
- Care 1st Health Plan
- Great West Healthcare-Cigna
- Coventry Health Care
- First Health (Coventry Health Care)
- Interplan Health Group
- Private HealthCare Systems
- Three Rivers Provider Network
- United Healthcare HMO
- United Healthcare PPO
Education
-
Harbor - UCLA Medical Center -
UCLA Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
City of Hope's Helford Clinical Research Hospital
Drug Facts
| NPI NUMBER | 1700938180 | |
| NPPES Provider LastName | PAL | |
| NPPES Provider FirstName | SUMANTA | |
| NPPES Provider ZIPCode | 910103012 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 148.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700938180 |
| Last Name Of The Provider | PAL |
| First Name Of The Provider | SUMANTA |
| View All |
Similar Doctors
|
Dr. George Somlo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Przemyslaw Twardowski, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vincent Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jana Portnow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanne Mortimer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Warren Chow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thehang H. Luu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Reckamp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melanie Palomares, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sangeeta S. Awasthi, MD
This Doctor is OpenDoctor Recommended.
|